晚期HIV门诊患者尿LAM检测在经验性抗结核治疗试验中的价值
本研究对ACTG A5274试验中850例CD4<50 cells/µL的HIV阳性门诊患者进行回顾性尿LAM检测,其中566例有检测结果,28例(5%)LAM阳性;
要点
- 在TB筛查阴性的晚期HIV门诊患者中,尿LAM检测可额外发现5%的结核病例。
- LAM阳性结果未改变经验性抗结核治疗对24周死亡率的影响。
- 排除LAM阳性者后,经验性治疗组结核发病率仍高于IPT组。
核心结论
- 在临床、显微镜和Xpert检测筛查阴性的晚期HIV门诊患者中,尿LAM检测可额外识别5%的结核病例,但LAM阳性结果未改变死亡率或结核发病率。
研究设计与样本
- 对ACTG A5274试验保存的基线尿液进行回顾性LAM检测,该试验纳入850例启动ART且CD4<50 cells/µL的HIV阳性成人。
- 采用改良意向性分析排除LAM阳性参与者,使用Kaplan-Meier法评估24周生存、结核发病率和至结核时间。
主要发现
- 850例参与者中566例(67%)有LAM检测结果,28例(5%)LAM阳性,经验性治疗组21例(7%)、IPT组7例(2%)。
- LAM阳性者中,经验性治疗组21例有5例发生结核、IPT组7例无发生;两组各1例死亡。
临床怎么用
- 对于CD4<50 cells/µL且TB筛查阴性的HIV门诊患者,可考虑尿LAM检测以发现额外结核病例。
- 尿LAM阳性结果不应单独作为启动经验性抗结核治疗的依据以改善生存。
局限性
- 回顾性设计,仅67%的参与者有保存尿液用于LAM检测。
- LAM阳性亚组样本量小,事件数少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The urine lipoarabinomannan (LAM) antigen test is a tuberculosis (TB) diagnostic test with highest sensitivity in individuals with advanced human immunodeficiency virus (HIV). Its role in TB diagnostic algorithms for HIV-positive outpatients remains unclear. METHODS: The AIDS Clinical Trials Group (ACTG) A5274 trial demonstrated that empiric TB therapy did not improve 24-week survival compared to isoniazid preventive therapy (IPT) in TB screen-negative HIV-positive adults initiating antiretroviral therapy with CD4 counts <50 cells/µL. Retrospective LAM testing was performed on stored urine obtained at baseline. We determined the proportion of LAM-positive participants and conducted modified intent-to-treat analysis excluding LAM-positive participants to determine the effect on 24-week survival, TB incidence, and time to TB using Kaplan-Meier method. RESULTS: A5274 enrolled 850 participants; 53% were male and the median CD4 count was 18 (interquartile range, 9-32) cells/µL. Of the 850, 566 (67%) had LAM testing (283 per arm); 28 (5%) were positive (21 [7%] and 7 [2%] in the empiric and IPT arms, respectively). Of those LAM-positive, 1 participant in each arm died and 5 of 21 and 0 of 7 in empiric and IPT arms, respectively, developed TB. After excluding these 28 cases, there were 19 and 21 deaths in the empiric and IPT arms, respectively (P = .88). TB incidence remained higher (4.6% vs 2%, P = .04) and time to TB remained faster in the empiric arm (P = .04). CONCLUSIONS: Among outpatients with advanced HIV who screened negative for TB by clinical symptoms, microscopy, and Xpert testing, LAM testing identified an additional 5% of individuals with TB. Positive LAM results did not change mortality or TB incidence.
引用
- Matoga MM, Bisson GP, Gupta A, et al. Urine Lipoarabinomannan Testing in Adults With Advanced Human Immunodeficiency Virus in a Trial of Empiric Tuberculosis Therapy. Clin Infect Dis. 2021. PMID: 34398958. doi:10.1093/cid/ciab179
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。